The SMART compounds also equi-potently inhibit the growth of parental and MDRover-expressing cells in vitro, indicating that they can overcome multidrug resistance. In vivo anti-tumor efficacy studies in human prostate (PC-3) and melanoma (A375) cancer xenograft models demonstrated that SMART-H and SMART-F treatments resulted in %T/C values ranging from 4-30%. In addition, in vivo SMART-H treatment for 21 days at the higher dose (15 mg/kg) failed to produce any apparent neurotoxicity. These studies provide the first in vivo evidence and proof-of-concept that SMART compounds are similarly efficacious to currently FDA approved antitubulin drugs for cancer treatment, but they can circumvent P-glycoprotein-mediated drug resistance.
Introduction
Microtubules, composed of αβ-tubulin heterodimers, play an important role in cell mitosis, motility and organelle distribution (1) . Formation of microtubules from tubulin is a dynamic process that involves polymerization and depolymerization and is crucial for mitosis (2) . Interference with tubulin-microtubule dynamics is one of the most attractive and successful molecular strategies to treat cancer (3, 4) . Paclitaxel, docetaxel, ixabepilone and three vinca alkaloids (vinblastine, vincristine, and vinorelbine), all FDA approved drugs, effectively inhibit tubulin action and successfully treat cancer (5) .
The taxanes and epothilones are semi-synthetic natural products that stabilize microtubules and cause apoptosis (5) . Paclitaxel and ixabepilone occupy overlapping binding sites on the surface of β-tubulin (6) and demonstrate nanomolar cytotoxicity in a variety of cancer cell lines. Unlike paclitaxel and docetaxel, ixabepilone demonstrates reduced susceptibility to drug resistance mechanisms that limit the effectiveness of taxanes, anthracyclines and a host of other anticancer agents (7) . The over-expression of ATP binding cassette (ABC) proteins, most notably P-glycoprotein (P-gp), in many cancer cells and tumors results in innate or acquired resistance to chemotherapy (8) . The ability of ixabepilone to circumvent these multidrug resistance (MDR) mechanisms has provided a unique chemotherapeutic approach for patients with anthracyclines or taxanes resistant tumors. An orally bioavailable sulfonamide (ABT-751) that inhibits tubulin polymerization and maintains activity in cells expressing P-glycoprotein is currently being evaluated in phase I trials (9, 10), but is not yet available for routine clinical use.
Despite the widespread use of the vinca alkaloids for the treatment of cancer and their susceptibility to these same MDR mechanisms, an anticancer agent that destabilizes In vivo PK profile of SMART compounds. A single bolus dose of SMART-F and -OH (15 mg/kg) was administered by tail vein injection to ICR mice to characterize their pharmacokinetics (Fig. 3A) . SMART-H and -F exhibited similar PK properties, but SMART-OH exhibited slightly greater AUC than SMART-H and SMART-F, indicative of a lower clearance for SMART-OH (Table 2) . SMART-OH also had 2-3 times higher V ss than that of SMART-H and -F. The clearance values for all three SMARTs were ≥ 90 ml/min/kg (the hepatic blood flow rate in mice (13)), suggesting that in addition to hepatic removal, other degradation routes may be involved in the elimination of SMARTs.
The pharmacokinetics of SMART-F (2.5 mg/kg) was also examined in rats (Fig. 3B) .
Interestingly, low clearance values and hepatic extraction rates were obtained by SMART-F and -H ( Table 2 ), suggesting that SMART compounds exhibit species differences in clearance. In rats, SMART-H and -F exhibited favorable pharmacokinetic properties, which are low clearance, moderate volume of distribution, long half-life, and high exposure (AUC) ( Table 2) . Colchicine and vinblastine were used as positive controls.
